HONG KONG, March 23, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced that its audited consolidated annual results for the year ended December 31, 2025 (the "Reporting Period"). During the Reporting Period, the Group's clear strategic focus and disciplined execution drove steady revenue and profit growth, supported by strong injectables momentum and robust expansion across international markets.
FINANCIAL HIGHLIGHTS
Revenue was US$365.3 million, representing an increase of 4.7% year on year ("YoY").
Revenue from injectables was US$28.0 million, representing an increase of 185.6% YoY.
International markets[1] (excluding North America) grew 20.1% YoY.
Revenue in APAC increased by 26.9% YoY to US$147.4 million, accounting for 40.4% of total revenue and making it the Company's largest revenue-contributing region. Revenues in Europe, and Middle East and Africa were US$56.4 million and US$36.4 million, representing increases of 11.7% YoY and 5.3% YoY respectively. Revenue in North America was US$111.0 million, representing a decrease of 19.2% YoY.
Gross profit margin was 58.9%, compared with 62.1% in 2024, mainly due to changes in geographic and product mix, as well as newly established import tariffs.
Net profit decreased by 13.1% YoY to US$25.0 million from US$28.8 million in 2024. Net profit margin was 6.8%, compared with 8.2% in 2024. Adjusted net profit increased by 7.9% YoY to US$31.0 million from US$28.7 million in 2024. Adjusted net profit margin was 8.5%, compared with 8.2% in 2024.
FINAL DIVIDEND
The Board has resolved to declare a final dividend of HK$0.095 per share (inclusive of tax) for the year ended December 31, 2025.
KEY ACHIEVEMENTS
EBD Reinforcing Core Strengths and Industry Leadership
Sisram's energy-based device portfolio continued to reinforce the Company's leadership in the global aesthetics market. Alma Harmony maintained strong international traction, with its Harmony Bio-Boost treatment receiving multiple prestigious recognitions, including the ELLE Awards, positioning the platform among leading patient choices. Alma Hybrid also delivered its fifth consecutive year of growth, highlighting the durability of the Company's core EBD platforms. In China, the launch ...
